TY - JOUR
T1 - Southwestern oncology Group phase II trial (S0526) of pemetrexed in bronchioloalveolar carcinoma subtypes of advanced adenocarcinoma
AU - Lau, Derick H.M.
AU - Moon, James
AU - Davies, Angela M.
AU - Sanborn, Rachel E.
AU - Hirsch, Fred R.
AU - Franklin, Wilbur A.
AU - Ruzich, Janet C.
AU - Redman, Mary W.
AU - Gandara, David R.
N1 - Funding Information:
This investigation was supported in part by the following Public Health Services Cooperative Agreement grant numbers awarded by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services : CA32102 , CA38926 , CA45377 , CA45560 , CA58882 , CA35090 , CA20319 , CA46441 , CA63844 , CA11083 , CA67663 , CA42777 , CA37981 , CA12644 , and in part by Eli Lilly and Company , and Response Genetics .
PY - 2013/7
Y1 - 2013/7
N2 - Background: Pemetrexed, a multitargeted antifolate drug, is an active agent in non-small-cell lung cancer (NSCLC), especially adenocarcinomas. Based on preclinical data supporting the relevance of alpha-folate receptors in adenocarcinoma of the bronchioloalveolar carcinoma (BAC) subtype, this trial was designed to assess pemetrexed in patients with this pathologic subtype of lung adenocarcinoma. Patients and Methods: Patients with histologically confirmed stage IIIB (with malignant pleural effusion) or stage IV adenocarcinoma with BAC features or pure BAC were eligible. Treatment consisted of pemetrexed, 500 mg/m2, administered intravenously every 21 days. Results: Of 27 patients enrolled, 24 were eligible and assessable for adverse events: Toxicity was primarily hematologic, consisting of leukopenia/neutropenia, thrombocytopenia, and anemia. The median follow-up among patients still alive (n = 8) was 35 months (range, 26-47 months). Among 17 patients with measurable disease, the response rate was 23% (all partial responses; 95% confidence interval [CI], 10%-56%). The median progression-free survival (PFS) and overall survival (OS) were 6 and 25 months, respectively. Conclusion: Pemetrexed is active and well tolerated and, in patients with adenocarcinoma BAC subtypes, likely related to its underlying mechanism of action as a multitargeted antifolate drug.
AB - Background: Pemetrexed, a multitargeted antifolate drug, is an active agent in non-small-cell lung cancer (NSCLC), especially adenocarcinomas. Based on preclinical data supporting the relevance of alpha-folate receptors in adenocarcinoma of the bronchioloalveolar carcinoma (BAC) subtype, this trial was designed to assess pemetrexed in patients with this pathologic subtype of lung adenocarcinoma. Patients and Methods: Patients with histologically confirmed stage IIIB (with malignant pleural effusion) or stage IV adenocarcinoma with BAC features or pure BAC were eligible. Treatment consisted of pemetrexed, 500 mg/m2, administered intravenously every 21 days. Results: Of 27 patients enrolled, 24 were eligible and assessable for adverse events: Toxicity was primarily hematologic, consisting of leukopenia/neutropenia, thrombocytopenia, and anemia. The median follow-up among patients still alive (n = 8) was 35 months (range, 26-47 months). Among 17 patients with measurable disease, the response rate was 23% (all partial responses; 95% confidence interval [CI], 10%-56%). The median progression-free survival (PFS) and overall survival (OS) were 6 and 25 months, respectively. Conclusion: Pemetrexed is active and well tolerated and, in patients with adenocarcinoma BAC subtypes, likely related to its underlying mechanism of action as a multitargeted antifolate drug.
KW - Bronchioloalveolar carcinoma (BAC)
KW - Lung adenocarcinoma
KW - Pemetrexed
UR - http://www.scopus.com/inward/record.url?scp=84878812253&partnerID=8YFLogxK
U2 - 10.1016/j.cllc.2012.12.004
DO - 10.1016/j.cllc.2012.12.004
M3 - Article
C2 - 23415808
AN - SCOPUS:84878812253
SN - 1525-7304
VL - 14
SP - 351
EP - 355
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 4
ER -